Sulfoximine glycosidase inhibitors

A compound of formula (I)

• wherein
• R is straight chain or branched alkyl having 1 to 6 carbon atoms, wherein 1 to 5 hydrogen atoms may be replaced by Hal or OH;
• W is CH or N;
• A denotes one of the following groups:
• X is N or CR′″;
• Y is O, S, SO or SO2;
• R′, R″ denote each independently H, Hal or straight chain or branched alkyl having 1 to 12 carbon atoms;
• R′″, R″″ independently denote H, Hal, NR3R4, CHR3R4, OR3, CN or a straight chain or branched alkyl having 1 to 12 carbon atoms, wherein 1 to 3 CH2-groups may be replaced by a group selected from O, NR3, S, SO, SO2, S(O)(NR3′), N(SO)R3′, CO, COO, OCO, CONR3, NR3CO,
• and wherein 1 to 5 hydrogen atoms may be replaced by Hal, NR3R4 or NO2 or by one of the following groups:
• or R′″, R″″ independently denote one of the following groups:
• R3, R4 denote each independently H or a straight chain or branched alkyl group having 1 to 12 carbon atoms;
• Q denotes one of the following groups:
• Z1 is S, O, NR3;
• Z2, Z3 independently denote CR5 or N;
• Z4 is N, CH, CON, COCH;
• Z5 is NR8, CHR5, S(O)(NR3′), N(SO)R3′,
• Z6 is CH2, CO, S(O)(NR3′), N(SO)R3′,
• Z7 is C(R3′)2, S, O, NR3′;
• s denotes 0 or 1;
• T is N, CH or CR7;
• R3′ denotes H or a straight chain or branched alkyl group having 1 to 12 carbon atoms, wherein 1 to 3 CH2-groups may be replaced by a group selected from SO2, CO, O and wherein 1 to 5 hydrogen atoms may be replaced by Hal;
• R5, R6, R7 independently denote H, Hal, NR3R4, NO2 or a straight chain or branched alkyl having 1 to 12 carbon atoms, wherein 1 to 3 CH2-groups may be replaced by a group selected from O, NR3, S, SO, SO2, S(O)(NR3′), N(SO)R3′, CO, COO, OCO, CONR3, NR3CO
• and wherein 1 to 5 hydrogen atoms may be replaced by Hal, NR3R4, NO2, OR3, Het, Ar, Cyc, or by one of the following groups:
• or R5, R6, R7 denote Ar, Het or Cyc or one of the following groups:
• R8 denotes H or straight chain or branched alkyl having 1 to 12 carbon atoms, wherein 1 to 3 CH2-groups may be replaced by a group selected from SO, SO2, S(O)(NR3′) N(SO)R3′, CO, COO, OCO, CONR3, NR3CO, and
• and further wherein 1 to 5 hydrogen atoms may be replaced by CN, OR3, SR3, Hal, NR3R4, NO2 or by one of the following groups:
• or R8 denote one of the following groups:
• Hal denotes F, Cl, Br or I;
• Het denotes a saturated, unsaturated or aromatic ring, being monocyclic or bicyclic or fused-bicyclic and having 3- to 8-members and containing 1 to 4 heteroatoms selected from N, O and S, which may be substituted by 1 to 3 substituents selected from R5, Hal and OR3;
• Ar denotes a 6-membered carbocyclic aromatic ring or a fused or non-fused bicyclic aromatic ring system, which is optionally substituted by 1 to 3 substituents independently selected from R5, OR3 and Hal;
• Cyc denotes a saturated or an unsaturated carbocyclic ring having from 3 to 8 carbon atoms which is optionally substituted by 1 to 3 substituents independently selected from R5 or Hal or OH;
• m and n denote independently from one another 0, 1, 2 or 3,
• t and q denote independently from one another 0, 1, 2 or 3, with t+q≥1
• and wherein at least one of Z5 and Z6 is the group S(O)(NR3′) or N(SO)R3′ or
• or
• wherein at least one of R′″, R″″, R5, R6, R7 and R8 is or contains a sulfoximine group selected from:
• or
• wherein at least one of R′″, R″″, R5, R6, R7 and R8 is selected from a straight chain or branched alkyl group having 1 to 12 carbon atoms, wherein at least one CH2-group is replaced by the group S(O)(NR3′) or N(SO)R3′ or
• or a pharmaceutically usable derivative, solvate, salt, prodrug, tautomer, enantiomer, racemate, or a stereoisomer thereof, including mixtures thereof in all ratios, or a compound of formula I wherein one or more H atoms are replaced by D (deuterium),
• with the proviso that the following compounds are excluded: